Hyperfine, Inc. (NASDAQ:HYPR - Get Free Report)'s share price dropped 1.5% on Tuesday . The stock traded as low as $0.99 and last traded at $1.00. Approximately 58,292 shares changed hands during mid-day trading, a decline of 44% from the average daily volume of 104,229 shares. The stock had previously closed at $1.01.
Hyperfine Price Performance
The firm has a market capitalization of $70.88 million, a price-to-earnings ratio of -1.67 and a beta of 0.84. The stock has a fifty day moving average of $1.07 and a two-hundred day moving average of $0.99.
Hyperfine (NASDAQ:HYPR - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.14) earnings per share for the quarter, meeting the consensus estimate of ($0.14). The company had revenue of $3.63 million during the quarter, compared to analysts' expectations of $3.15 million. Hyperfine had a negative return on equity of 51.72% and a negative net margin of 347.05%. During the same quarter in the prior year, the firm posted ($0.15) earnings per share. On average, research analysts forecast that Hyperfine, Inc. will post -0.57 EPS for the current year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Hyperfine stock. Journey Strategic Wealth LLC bought a new position in shares of Hyperfine, Inc. (NASDAQ:HYPR - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 74,929 shares of the company's stock, valued at approximately $84,000. Journey Strategic Wealth LLC owned about 0.10% of Hyperfine as of its most recent SEC filing. Institutional investors and hedge funds own 15.03% of the company's stock.
Hyperfine Company Profile
(
Get Free Report)
Hyperfine, Inc, a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors.
Recommended Stories
Before you consider Hyperfine, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hyperfine wasn't on the list.
While Hyperfine currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.